az

AstraZeneca’s Brilinta reduces the rate of stroke and death in patients with acute ischaemic stroke or transient ischaemic attack

pharmafile | July 16, 2020 | News story | Business Services AZ, AstraZeneca, drug trials 

AstraZeneca’s Phase 3 THALES trial showed that Brilinta (ticagrelor) significantly reduced the rate of death or stroke in patients with acute ischaemic stroke or transient ischaemic attack (TIA).

The results were published in The New England Journal of Medicine, and patients took 90mg of Brilinta twice daily with aspirin for 30 days. This reduced the rate of the primary endpoint of stroke and death by 17% compared to aspirin alone in TIA patients. This was a statistically significant and a clinically meaningful reduction. Brilinta combined with aspiring also significantly reduced the rate of schaemic stroke by 21%, compared to aspirin alone up to day 30.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said: “Patients who had an acute ischaemic stroke or transient ischemic attack may experience a subsequent, potentially avoidable stroke. Results from the Phase III THALES trial confirm that aspirin plus Brilinta has the potential to be a new effective treatment option for these high-risk patients and we look forward to continuing discussions with regulatory authorities.”

The FDA accepted a New Drug Application and granted a Priority Review for Brilinta for TIA based on this Phase 3 trial. It is already approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.

Conor Kavanagh

Related Content

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …

Latest content